PALO ALTO, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that management is scheduled to present at the 8th Annual OneMedForum and the 7th Annual BioTech Showcase investor conferences held in San Francisco, CA from January 12 – 14. Management will also participate on a panel discussion titled "Investing in the Immuno-Oncology Revolution" on January 14 at the BioTech Showcase.
These major life science investor events bring together investors, regenerative medicine and biopharmaceutical executives from around the world to present and discuss the latest in healthcare innovation. Over 2,000 executive-level delegates representing qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives as well as other industry professionals are expected to attend. Company management will be available to participate in one-on-one meetings with investors and strategic partners during these conferences.
Event: OneMedForum
Speaker: Tony (Bizuo) Liu, Chief Financial Officer
Presentation: Corporate Overview
Location: San Francisco Marriot Marquis, 780 Mission Street
Date: Tuesday January 13, 2015
Time: 1:40-2:00 PM (PST)
Webcast: www.onemedforum.com
Event: BioTech Showcase
Speaker: William (Wei) Cao, BM, PhD, Chief Executive Officer
Panel Discussion: Investing in the Immuno-Oncology Revolution
Location: San Francisco Parc 55 Wyndham Union Square Hotel
Date: Wednesday January 14, 2015
Time: 8:00-9:00 AM (PST)
Event: BioTech Showcase
Speaker: William (Wei) Cao, BM, PhD, Chief Executive Officer
Presentation: Corporate Overview
Location: San Francisco Parc 55 Wyndham Union Square Hotel
Date: Wednesday January 14, 2015
Time: 10:30-11:00 AM (PST)
Management will deliver presentations and provide an overview of the Company's business operations including 2014 milestone accomplishments and revenue growth, and will discuss its 2015 projected growth plan and upcoming milestones. The Company's proprietary therapies in various stages of research and development include:
-
ReJoinTM human adipose derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA) and Cartilage Damage (CD)
-
CentrixTTM autologous central memory T-cell (Tcm) immunotherapy for Cancer
-
Immune function evaluation systems for the clinical studies of Cancer
-
Human adipose derived mesenchymal progenitor cell (haMPC) therapy for Asthma
To arrange a meeting with management, please contact Vivian Chen, Managing Director Investor Relations, Grayling at vivian.chen@grayling.com.
To register for the events or for more information, please visit the event websites:
http://www.onemedconferences.com/
http://www.ebdgroup.com/bts/program/index.php
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
